Recruiting
Phase 3

SEXTANT

Sponsor:

Major Extremity Trauma Research Consortium

Code:

NCT04678154

Conditions

Post Operative Surgical Site Infection

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Not accepted

Interventions

Standard of care

Vancomycin and Tobramycin

Study Details

Brief summary:

The PRCT evaluates infection outcomes as well as fracture and antibiotic-related complications to include the emergence of resistant bacteria associated with two different antibiotic strategies in the treatment of Gustilo type IIIB tibia and hindfoot fractures (calcaneus and talus) and selected IIIA fractures of the tibia and trauma-related transtibial amputations that are performed in the "zone-of-injury". This study will be conducted in established METRC level 1 trauma centers.

The patients will be randomized as close to admission as possible to either 1) Standard of Care (SOC) prophylactic open fracture protocol, including the use of topical antibiotic as per the usual practice of the surgeon or 2) experimental protocol (SEXTANT). The SEXTANT protocol includes application of wound bioburden-targeted topical Vancomycin powder and Tobramycin powder antibiotic treatment at the time of final wound closure/coverage combined with 72 hours of systemic antibiotic coverage targeted to both gram-positive and gram-negative pathogens. The study will compare the results of the current SOC prophylactic coverage to the strategic wound bioburden treatment (SEXTANT) protocol.

Up until the time of definitive wound closure/coverage, all patients will be treated per the usual regimen of the surgeon / center and in accordance with current Trauma Quality Improvement Program (TQIP) and Surgical Quality Improvement Program (SQIP) recommendations for the care of open fractures.14,15,17 It includes the administration of systemic antibiotics as close to the time of injury as possible.

In the definitive wound closure/coverage procedure post-operative period, participants in the intervention arm will receive 72 hours of systemic antibiotic therapy targeted at the modern wound bioburden, and patients in the usual care arm will receive post-operative care per the usual practice of their surgeon. All other activities related to follow-up and related treatments will proceed per the usual practice of the surgeon.

Conditions

Post Operative Surgical Site Infection

Study ID

NCT04678154

Start date

May 7, 2021

Status verified date

Jun, 2026

Completion date

Mar 31, 2029

Anticipated

Primary completion date

Sep 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Injury meeting at least one of the following criteria:

a. Gustilo type III fractures of the tibia (OTA 41 plateau, OTA 42 shaft and OTA 43 pilon); ankle (OTA 44); calcaneus (OTA 82) and/or talus (OTA 81) with injury characteristics meeting at least one of the following criteria: i. All IIIB fractures ii. IIIA fractures that require a planned second debridement prior to definitive closure / coverage iii. IIIA fractures with extensive contamination or muscle damage precluding definitive internal fixation at the time of initial surgery iv. IIIA fractures with extensive degloving or wound greater than 10 cm after debridement (if indicated, primary wound closure is allowed. Primary wound closure refers to the definitive closure of the wound at the initial surgical event, without plans for re-entry for additional debridement and/or fracture fixation) v. IIIA fractures severe fracture comminution resulting from high energy trauma (if indicated, primary wound closure/coverage is allowed) vi. IIIA fractures with AO/OTA OFC contamination level of severe with material imbedded into bone or soft tissue or with a severe high risk environmental contamination from farm, fecal, dirty water inoculation or other equivalent (if indicated, primary wound closure/coverage is allowed) vii. IIIA Fractures where the skin could be closed after extensive muscle or bone removal (if indicated, primary wound closure/coverage is allowed) viii. IIIA fractures with bone loss resulting in a circumferential gap of 1 cm after debridement (if indicated, primary wound closure/coverage is allowed) ix. Fractures where fasciotomies were performed for impending or diagnosed compartment syndromes (regardless of the initial open or closed classification of the fracture x. Traumatic "zone-of-injury" trans-tibial amputations requiring DPC, and/or flap coverage
2. Ages 18 - 64 years inclusive
3. Patients may have risk factors for infection including diabetes, immunosuppression from steroids or other medications, HIV, or other infections.
4. Patients may have a traumatic brain injury.
5. Patients may have other fractures including spine, upper extremity fractures, contralateral lower extremity injuries, ipsilateral pelvis, hip, femur, or foot injuries.
6. Patients may be treated initially at an outside institution prior to transferring to the study institution, as long as the definitive wound closure/coverage was not performed prior to entrance into the study.
7. Patients with bilateral injuries that meet inclusion criteria may be included, but only the limb rated as "more severe" by the treating surgeon will be enrolled in the study.
8. Patients may have co-existing non-tibial or hindfoot infections, with or without antibiotic treatment.
9. Patients may be definitively stabilized using any method (nail, plate, ex fix, or cast).
10. Patients may have fasciotomy.

Exclusion Criteria:

1. Patient speaks neither English or Spanish
2. Patient in current therapy for a wound, implant or fracture site infection related to the study site.
3. Patient is pregnant, potentially pregnant, or lactating.
4. Patient likely to have difficulty maintaining follow-up, including:

1. Diagnosis of a severe psychiatric condition
2. Intellectually challenged without adequate family support
3. Resides outside of the hospital's catchment area, unless willing to follow-up by phone or telemedicine
4. Planning to follow-up at another medical center, unless willing to follow-up by phone or telemedicine
5. Being a prisoner
6. Not having a means of contact (address, cell phone, home phone, e-mail)

Study Design

Enrollment

600 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Control

Participants in the control group will receive standard care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Topical antibiotics are allowed, if SOC for the institution, but are not mandated.

experimental: Treatment

The patients in the SEXTANT cohort will receive 72 hours of targeted systemic antibiotic therapy (Table 2) and will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site, and exposed hardware (if any) just prior to suture closure of the wound or flap.

Interventions

Standard of care

Participants in the control group will receive standard care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Topical antibiotics are allowed, if SOC for the institution, but are not mandated.

Vancomycin and Tobramycin

The patients in the SEXTANT cohort will receive 72 hours of targeted systemic antibiotic therapy (Table 2) and will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site, and exposed hardware (if any) just prior to suture closure of the wound or flap.

72-hour of systemic gram-positive and gram-negative antibiotic coverage to target the terminal wound bioburden. The antibiotics coverage proposed as the primary choice includes PO Ciprofloxacin + PO linezolid or IV Ciprofloxacin and IV Vancomycin.

The preferred antibiotic regimen will be decided by study's ID team, in cooperation with the ID and Antibiotic Stewardship teams at each site. Antibiotic recommendations will be adjusted, if needed, to account for a Site's bacteria susceptibility / resistance profile, or the specific needs of an individual patient.

Primary outcome measure

  • Deep surgical site infection [ Time Frame: 180 days from final wound closure/cloverage ]

Central Contacts and Locations

Central contacts

Locations

Stanford University

Recruiting

Redwood City, California, United States, 94063

Contacts

_University of California, San Francisco

Recruiting

San Francisco, California, United States, 94110

Contacts

University of California at San Francisco

Recruiting

San Francisco, California, United States, 94110

Contacts

Eleni Berhaneselase

Eleni.Berhaneselase@ucsf.edu

Principal Investigator:

Saam Morshed, MD

University of Colorado Anschutz Medical Campus

Recruiting

Aurora, Colorado, United States, 80045

Contacts

St Mary's University/Tenent Health

Recruiting

West Palm Beach, Florida, United States, 33407

Contacts

Emory University School of Medicine

Recruiting

Atlanta, Georgia, United States, 30303

Principal Investigator:

William Reisman, MD

Indiana University School of Medicine - Methodist Hospital

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Indiana University/Eskenazi Health

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

University of Kentucky

Recruiting

Lexington, Kentucky, United States, 40506

Contacts

LSU Health Sciences

Recruiting

New Orleans, Louisiana, United States, 70112

Contacts

Jessica Rivera

jrive5@lsuhsc.edu

University of Maryland , MD Department of Orthopaedics

Recruiting

Baltimore, Maryland, United States, 21201

Contacts

Yasmin Degani, MPH

ydegani@som.umaryland.edu

Principal Investigator:

Robert O'Toole, MD

Walter Reed Military Medical Center

Recruiting

Bethesda, Maryland, United States, 20889

Contacts

Harvard/Mass General/Brigham Hospitals

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Hennepin County Medical Center / Minneapolis

Recruiting

Minneapolis, Minnesota, United States, 55415

Principal Investigator:

Andrew Schmidt, MD

University of Mississippi Medical Center

Recruiting

Jackson, Mississippi, United States, 39216

Contacts

Dartmouth Hitchcock

Recruiting

Lebanon, New Hampshire, United States, 03766

Contacts

Jamaica Hospital Medical Center

Recruiting

Jamaica, New York, United States, 11418

Principal Investigator:

Sanjit Konda, MD

University of North Carolina at Chapel Hill

Recruiting

Chapel Hill, North Carolina, United States, 27514

Contacts

Atrium Health Carolinas Medical Center

Recruiting

Charlotte, North Carolina, United States, 28203

Atrium Health Wake Forest Baptist

Recruiting

Winston-Salem, North Carolina, United States, 27157

Contacts

METROHealth

Recruiting

Cleveland, Ohio, United States, 44109

Contacts

Ohio State University Wexner Medical Center

Recruiting

Columbus, Ohio, United States, 43201

Contacts

University of Oklahoma College of Medicine

Recruiting

Oklahoma City, Oklahoma, United States, 73104

Contacts

Temple University

Recruiting

Philadelphia, Pennsylvania, United States, 19140

Contacts

Brown University/Rhode Island Hospital

Recruiting

Providence, Rhode Island, United States, 02905

Principal Investigator:

Roman Hayda, MD

Rhode Island Hospital/Brown University

Recruiting

Providence, Rhode Island, United States, 02905

Contacts

Vanderbilt University Medical Center

Recruiting

Nashville, Tennessee, United States, 37232

Contacts

Principal Investigator:

William T. Obremskey, MD

University of Texas Health Science Center - Houston

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Stephen Warner, MD

University of Virginia

Recruiting

Charlottesville, Virginia, United States, 22903

Contacts

Principal Investigator:

David Weiss, MD

Inova Fairfax MEdical Campus

Recruiting

Falls Church, Virginia, United States, 22042

Contacts

Virginia Commonwealth University Medical Center

Recruiting

Richmond, Virginia, United States, 23298

Contacts

More Information

Sponsor

Major Extremity Trauma Research Consortium

Last update posted

Jul 22, 2026

Last verified

Jun, 2026

Keywords

  • Surgical site infection risk prevention
  • Bacterial species type and antibacterial sensitivities

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Major Extremity Trauma Research Consortium on 2026-07-22.